Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Clinical trial NCT04784715 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04784715
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-26
- Primary completion
- 2026-11-11
- Enrollment
- 1157
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.